These results are simply amazing. One wonders how the FDA could ignore this latest data (but who knows).
This is Long-term evidence of survival of children treated with remestemcel-L, through 4 years. Four years !!!
Overall survival at 2 years was 51% in remestemcel-L treated children, as opposed to just 25-38% if they received best available therapy(BAT)
In the words of the company ... "These long-term survival outcomes are a key component of the Biologics License Application(BLA) resubmission to the United States Food and Drug Administration (FDA)" So now we know.
Finally we should see 'daylight' with the FDA. These data speak for themselves.
Opinion only of course.
Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel, page-2
-
- There are more pages in this discussion • 354 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
98.0¢ |
Change
0.010(1.03%) |
Mkt cap ! $1.118B | |||
| Open | High | Low | Value | Volume |
| 96.0¢ | 99.0¢ | 95.5¢ | $5.286M | 5.409M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 91218 | 98.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.0¢ | 63577 | 4 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |